Market Place
Sourcing Support
Capricor, PPMD Host Webinar on Deramiocel for Duchenne Treatment
28 Jul 2025 //
GLOBENEWSWIRE
Capricor Shares Sink After FDA Declines Approval for Muscle Drug
11 Jul 2025 //
REUTERS
Capricor Therapeutics Appoints Michael Binks as CMO
13 May 2025 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Leerink`s Healthcare Conf. 2025
07 Mar 2025 //
GLOBENEWSWIRE
Capricor Therapeutics to Present Q3 2024 Results on Nov 13
05 Nov 2024 //
GLOBENEWSWIRE
Capricor sells Europe rights to DMD therapy for $35M FDA application approaches
19 Sep 2024 //
FIERCE BIOTECH
Capricor Therapeutics To Report Q2 2024 Results On August 7
31 Jul 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
01 Jul 2024 //
GLOBENEWSWIRE
Capricor Reports Long-Term Benefits Of Deramiocel In Duchenne Muscular Dystrophy
28 Jun 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
25 Jun 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Q1 2024 Financials, Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Capricor Exosome Platform Update At ASGCT Annual Meeting 2024
09 May 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
08 May 2024 //
GLOBENEWSWIRE
Capricor To Present Q1 2024 Results, Updates On May 13
06 May 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Investor Conferences
21 Mar 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Presents at 2024 MDA Clinical & Scientific Conference
06 Mar 2024 //
GLOBENEWSWIRE
Capricor Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA
27 Feb 2024 //
GLOBENEWSWIRE
Capricor to Present Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production
20 Feb 2024 //
GLOBENEWSWIRE
Capricor Announces Collaboration with the National Institutes of Health
24 Jan 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Capricor Therapeutics to Present Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar
19 Oct 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Presentations at 28th Annual Congress
10 Oct 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Announces $23 Million Registered Direct Offering
29 Sep 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
06 Sep 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
PRESS RELEASE
Capricor Therapeutics to Present Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Capricor Announces Appointment of Philip J. Gotwals to its Board of Directors
24 Jul 2023 //
GLOBENEWSWIRE
Capricor Announces Appointment of Paul Auwaerter to its Board of Directors
13 Jul 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Capricor Therapeutics to Present 1Q 2023 FYR Recent Corporate Update on May 11
04 May 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Presents at 2023 (MDA) Clinical & Scientific Conference
23 Mar 2023 //
GLOBENEWSWIRE
Capricor Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Capricor inks $100 M deal with Nippon Shinyaku for DMD treatment in Japan
20 Feb 2023 //
BIOSPECTRUM ASIA
Capricor and Nippon Shinyaku Enter Partnership Distribution of CAP-1002
16 Feb 2023 //
GLOBENEWSWIRE
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar
19 Jan 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Reports 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Capricor Therapeutics to Present 3Q FYR and Recent Corporate Update on Nov 10
03 Nov 2022 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Investor Conferences
07 Sep 2022 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Q2 Financial Results and Provides Corporate Update
10 Aug 2022 //
GLOBENEWSWIRE
Capricor Txto Present Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
Capricor Tx Begins Dosing in Pivotal PIII Study of CAP-1002 in DMD
19 Jul 2022 //
GLOBENEWSWIRE
Capricor hits primary endpoint in DMD extension study, readying its FDA pitch
27 Jun 2022 //
ENDPTS
Capricor Tx Announces Statistically Significant Clinical Benefits from CAP-1002
27 Jun 2022 //
GLOBENEWSWIRE
Capricor to Present 1Y Efficacy Results from HOPE-2 Open Label Extension Study
17 Jun 2022 //
GLOBENEWSWIRE
Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer
25 May 2022 //
GLOBENEWSWIRE
Capricor Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Capricor Therapeutics to Present First Quarter 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
Capricor Therapeutics to Participate in the Cantor Fitzgerald ROD Summit
29 Mar 2022 //
GLOBENEWSWIRE
Capricor Tx Reports Topline Results from Phase 2 Exploratory INSPIRE Trial
28 Mar 2022 //
GLOBENEWSWIRE
Capricor Ditches COVID-19 Vaccine Program to Focus on DMD
12 Mar 2022 //
BIOSPACE
Capricor Tx Reports Q4 and FY 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Capricor Tx to Present Q4 and Full Year 2021 Financial Results
03 Mar 2022 //
GLOBENEWSWIRE
Capricor Tx Names Dr. Daniel Paulson as Vice President of Clinical Development
02 Mar 2022 //
GLOBENEWSWIRE
Capricor Tx, Nippon Shinyaku Partner for CAP-1002 in DMD
25 Jan 2022 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic
13 Dec 2021 //
GLOBENEWSWIRE
Capricor finds efficacy in older Duchenne patients in phase 2
25 Sep 2021 //
FIERCEBIOTECH
Capricor jumps 17% on positive CAP-1002 data from mid-stage DMD
24 Sep 2021 //
SEEKINGALPHA
